Euroapi S.A.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Euroapi S.A. (EAPI.PA) develops, manufactures, markets and distributes active pharmaceutical ingredients (APIs) and intermediates for human and veterinary medicines, generics, cosmetics and consumer health products; its portfolio encompasses approximately 200 products across categories including vitamin B12, prostaglandins, oligonucleotides, peptides, corticosteroids and hormones, anti-infectives, opiates such as morphine, codeine and thebaine, analgesics and alkaloids; the company provides contract development and manufacturing organization (CDMO) services, research and development capabilities, spray-drying, micronization, particle engineering, microbial fermentation and custom development for clinical studies. Euroapi operates six manufacturing sites across Europe in France (Saint-Aubin-lès-Elbeuf, Vertolaye), Italy (Brindisi), Germany (Frankfurt), Hungary (Budapest) and the United Kingdom (Haverhill), supplying customers in more than 80 countries with a workforce of around 3,450 employees. Headquartered in Paris, France, and founded in 2020 as a spin-off from Sanofi, Euroapi focuses on small molecules APIs with technologies supporting pharmaceutical, biotech, animal health, nutrition and distribution clients. Recent developments include the completion and financing of its FOCUS-27 strategic plan in October 2024 with Sanofi support; a October 2025 partnership with Abolis Biotechnologies under the Med4Cure IPCEI program to advance corticosteroid production and European pharmaceutical sovereignty via biotechnology and chemistry integration; selection in June 2024 for up to EUR 1 billion European Commission IPCEI funding in the pharmaceutical sector; a May 2024 CMO agreement with a global animal health company valued at EUR 130-150 million over 2025-2029; the 2023 acquisition of German CDMO BianoGMP for EUR 10 million to bolster oligonucleotide capabilities; and a January 2024 collaboration with SpiroChem CRO, alongside a temporary pause of Brindisi site production in March 2024 due to quality issues.
EUROAPI statement regarding the Brindisi site
EUROAPI - Availability of the 2025 Universal Registration Document
Euroapi S.A. (EAPIF) Q4 2025 Earnings Call Transcript
Euroapi S.A. (OTCMKTS:EAPIF) Short Interest Update
Abolis Biotechnologies and EUROAPI Enter Into Partnership to Accelerate Pharmaceutical Innovation and Restore European Sovereignty
With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty
Science Based Targets initiative (SBTi) validates EUROAPI's near-term climate targets
Euroapi: Public Financing, Reorganization, And Very Cheap
EUROAPI sells Haverhill site to Particle Dynamics as part of its FOCUS-27 transformation plan
Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities
EUROAPI moves into a new chapter with new Governance and Leadership
Olivier Falut appointed EUROAPI's Chief Financial Officer
EUROAPI closes the financing of its FOCUS-27 plan
EUROAPI completes the financing of its FOCUS-27 plan and moves forward with its execution
Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi
EUROAPI - Availability of 2024 Half-Year Financial Report
EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1
EUROAPI and Priothera enter into CDMO collaboration to advance oncology project
EUROAPI reaches major Health IPCEI milestone with official notification from European Commission
EUROAPI strengthens its presence in animal health with a €130-150 million supply contract